Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adipose-derived stem cells (ADSCs) combined with platelet-rich plasma (PRP) is an autologous cell therapy combination being evaluated by Assiut University for the treatment of androgenetic alopecia. This therapeutic approach involves the isolation of mesenchymal stem cells from adipose tissue, which are then suspended in PRP—a concentrated source of autologous platelets. The mechanism of action relies on the synergistic effect of growth factors and cytokines secreted by both the ADSCs (such as VEGF, HGF, and IGF-1) and the activated platelets (such as PDGF and TGF-β). These factors promote hair follicle cell proliferation, prolong the anagen phase of the hair cycle, and enhance angiogenesis in the scalp microenvironment. In the context of follicular unit extraction (FUE) hair transplantation, this combination is used to improve the survival and growth of transplanted hair follicles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adipose-derived stem cells + platelet-rich plasma.